In the current prospective study, our goal was to examine the role of plasma PEDF as a biomarker for the detection of chronic kidney disease (CKD) progression in patients with type 2 diabetes mellitus (T2DM) before progressing to severely reduced kidney function. This evidence concerns the gene SERPINF1 and type 2 diabetes mellitus.